In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allena Pharmaceuticals Inc.

http://www.allenapharma.com/

Latest From Allena Pharmaceuticals Inc.

Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients

The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.

Clinical Trials Rare Diseases

Allena Bets On Its Kidney Stone Treatment Despite Placebo Concerns

Execs are hoping having positive results in two studies will help raise funds for continued development. But high placebo results have caused concern for investors.

Clinical Trials Renal

Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive

Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.

Deals Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register